The Timeline: How One Sterilisation Request Became a Battle With the NHS
What began as one request for permanent contraception became a series of overlapping complaints, investigations, Freedom of Information requests, governance challenges and external escalations.
This page puts the major events into one chronology so that you can see what happened, how long each process took, when failures overlapped, and why I repeatedly had to move from one accountability route to another.
Last updated: 12 September 2026I ask my GP for permanent contraception. Instead of entering a normal clinical pathway where my informed choice can be considered, I discover that an Oxfordshire commissioning policy effectively blocks routine access to NHS-funded female sterilisation.
What initially looks like one healthcare decision becomes the starting point of a much bigger investigation into bodily autonomy, commissioning policy and unequal access.
I work through policy papers, committee records, cost arguments and clinical evidence, asking whether the ICB can actually substantiate the restrictions it has placed on women.
Questions emerge around cost-effectiveness, clinical guidance, side effects of alternative contraception, equality, informed choice and whether the NHS ever properly justified departing from national guidance.
My challenge is no longer simply about whether I personally receive sterilisation. I am challenging how the NHS created the policy, what evidence it relied on, whether equality was properly considered and whether my complaint was handled fairly.
After a long wait, the Parliamentary and Health Service Ombudsman investigation develops into a detailed examination of the policy, evidence, complaint handling and the ICB's explanations for its decision-making.
The findings expose problems involving evidence, consultation, decision-making, clinical guidance, equality considerations and complaint handling.
They also make the gap between what I had previously been told by Chief Executive Dr Nick Broughton and what the independent investigation found impossible for me to ignore.
Female sterilisation is no longer framed exactly as before, but the replacement policy introduces another barrier: women are expected to trial, or demonstrate the unsuitability of, Long-Acting Reversible Contraception before permanent contraception.
Following the Ombudsman findings, I ask whether the Board or Chair examined leadership accountability, whether Dr Broughton's Fit and Proper Person status had been reconsidered, and what governance route had been used.
At the same time, I challenge the continuing inequality and restrictions built into the replacement female sterilisation policy.
Dr Singh confirms that the Board, its committees and associated groups had not considered leadership accountability following the Ombudsman findings.
She also confirms that Dr Nick Broughton's Fit and Proper Person status had not been reviewed, reassessed or discussed as a result of those findings.
I ask whether NHS Thames Valley ICB considers the policy compliant with equality law, the Public Sector Equality Duty, the NHS Constitution, Montgomery, NICE and WHO guidance, informed consent, bodily autonomy and the Ombudsman's findings.
I repeatedly ask for a direct answer. I never receive one.
After repeatedly hitting a wall in correspondence with the Chair, I ask for the documentary evidence behind the February 2026 Female Sterilisation Policy.
I request approval records, equality analysis, clinical and legal rationale, comparison with vasectomy, consideration of informed consent and bodily autonomy, and evidence that the post-Ombudsman reforms to policy development were actually followed.
Dr Priya Singh tells me that women should be allowed to choose sterilisation after being informed about alternatives without first being required to undergo a LARC trial.
She says the new recommendation will go through Board-level scrutiny and Quality Committee approval, with a replacement policy expected in early autumn 2026, and promises that I will be notified when it is available.
After repeated chasers and requests for a direct answer, Dr Singh says the ICB considers there to be no further substantive issues to address.
She preserves one promise: I will be sent the revised female sterilisation policy when it is approved. As of 12 September 2026, I have heard nothing further from her.
The 20-working-day statutory deadline expires without the substantive disclosure. This eventually becomes a separate fight over transparency, FOI governance and leadership accountability.
I formally challenge the overdue FOI through an Internal Review and escalate the information-law failures to the Information Commissioner's Office.
At the same time, I approach the Oxfordshire Joint Health Overview and Scrutiny Committee about the wider female sterilisation inequality, governance and transparency issues.
After seeing NHS-funded vasectomy delivered through private providers, including self-referral routes, I ask the ICB who commissions these services, how men access them, what safeguards apply and what equality analysis has been done.
I also ask whether anyone considered giving women comparable access to NHS-funded permanent contraception through private providers or self-referral.
After the Chair confirms that Dr Nick Broughton was not reviewed following the Ombudsman findings, I take the leadership-accountability question beyond NHS Thames Valley ICB.
Information Governance Manager Mark Gittins confirms that the organisation failed to comply with the requirement to respond within the statutory timeframe.
The review also reveals wider questions about failed internal controls, restructuring, staffing, disputed redactions and who was responsible for the failure.
I make clear that this is no longer only about my legal right to information. I ask who allowed the controls to fail, why senior leadership did not intervene, how staff handled the request and what accountability will follow.
NHS Thames Valley ICB says the nine-year request would exceed the statutory cost limit after carrying out approximately ten hours of initial scoping across multiple teams and record systems.
I accept that the original request is broad — but ask the ICB to fulfil its Section 16 duty and tell me how to narrow it to something it can answer.
PPET says the ICO is the appropriate route because the failures arose around an FOI request. I repeatedly explain that I am asking something different: who inside the ICB will investigate staff conduct, failed controls, management response and executive accountability?
No internal investigator or alternative governance route is identified.
After I reduce the request to current providers, current access pathways, current equality assessment and the latest comparison with female sterilisation, the ICB still says it can identify no meaningful refinement.
I copy Chief Executive and Accountable Officer Dr Nick Broughton, Chair Dr Priya Singh and Chief Strategy and Commissioning Officer Hannah Iqbal so there can be no later claim that senior leadership did not know.
The response finally arrives after the statutory deadline of 6 July 2026 had been seriously missed.
But reviewing the disclosure reveals another problem: important post-Ombudsman records, approval evidence, equality material and parts of the governance audit trail appear to be missing.
After I approach the Oxfordshire Joint Health Overview and Scrutiny Committee asking it to examine unequal access to female sterilisation, governance failures and the lack of transparency at NHS Thames Valley ICB, I am told on 11 September 2026 that the issue will move into a future Women's Health scrutiny discussion.
The anticipated public meeting is in February 2027, meaning this strand of the battle now continues into another calendar year.
I identify missing post-Ombudsman feedback records, review documentation, equality material, the 14-item remedial action tracker, approval records, challenged redactions and other parts of the audit trail.
I give the ICB one final practical opportunity to correct the disclosure before adding the remaining failures to the wider external accountability evidence.
This is not a replacement statutory deadline. The legal FOIA deadline expired on 6 July 2026.
It is simply the final opportunity I am giving the ICB to provide the missing records and properly explain anything it still refuses to disclose before I move forward with the other accountability routes already underway.
The current anticipated date for Oxfordshire's public Women's Health scrutiny item, following my request that the Committee examine female sterilisation inequality, governance and transparency at NHS Thames Valley ICB.
